Turn Late-Stage Trial Data Into Higher Asset Value
TrialLens™ analyzes patient-level clinical trial data to identify responder profiles, non-responder patterns, adverse-event risks, and commercially valuable subgroup signals
Higher Asset Valuation
+10–25% asset valuation improvement
from clearer responder, safety, and subgroup evidence before fundraising, BD, or licensing discussions.
Lower Wasted Trial Spend
$2M–$15M in avoidable trial costs
from reducing wasted enrollment by 15–30%, depending on study size, indication, and trial design.
Faster Clinical Decisions
50–70% faster data exploration
saving 200–500 analyst hours per study across clinical, safety, and subgroup analysis.
Stronger Safety Interpretation
40–60% faster safety analysis
helping protect $5M–$50M in asset value through earlier and clearer safety-risk interpretation.
Client Implementations
Real clinical-data intelligence systems — adapted to each asset, dataset, and development strategy.
Trusted by Industry Leaders:
Start with a free demo on your own data
See how the solution works in practice before committing to deployment or integration.
No-charge initial demo
Get in touch with us.
We’re here to assist you.
